REQUEST FOR PROPOSALS SAYANA PRESS SELF-INJECTION STUDY IN MALAWI

Transcription

1 REQUEST FOR PROPOSALS SAYANA PRESS SELF-INJECTION STUDY IN MALAWI RFQ Date of Issuance: 09/ 3 / 14 Due Date for Questions: 09/ 15 / 14 Due Date for Proposals: 09/ 25 / 14 Period of Performance: October 15, 2014 December 30, 2016 Background Sayana Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject (Pfizer, Inc., USA). Sayana Press was registered with the Medicines and Health Care Products Regulatory Agency (MHRA) and several other national regulatory agencies. Recent FHI 360 studies in Uganda and Senegal found that a high percentage ( 80%) clients and providers preferred Sayana Press over the usual DMPA intramuscular (DMPA-IM) injection [1,2]. These studies provided evidence that Sayana Press can be safely introduced into family planning programs and administered by trained community health workers, with expectation of client uptake. Work is currently underway to introduce the delivery of Sayana Press through health care providers in Uganda, Senegal, and other select countries. The potential advantages of Sayana Press include: Ease of administration to allow use by health workers who do not normally give injections Single dose to minimize wastage and facilitate outreach to individual clients Prefilled to ensure the correct dose is given and simplify procurement and logistics All in one to eliminate need to bundle vials and syringes and to prevent potential mismatches at the service delivery point Nonreusable to minimize patient-to-patient transmission of blood borne pathogens through needle reuse Compact size for easy transport, storage, and disposal The addition of this method is anticipated to aid in improving provision of family planning services in low-resource settings. As such, Sayana Press could be particularly useful in a country such as Malawi where injectable contraception is the most common method used but the contraceptive prevalence rate for modern methods is currently only 42% and the total fertility rate has only declined from 6.7 in 1992 to 5.7 in 2010 [3,4] due to a number of factors affecting access to family planning services, including distance to clinics and health care worker shortages. 1

2 A barrier to rapid programmatic uptake of Sayana Press is its anticipated higher cost relative to DMPA- IM. Costs can be significantly reduced if Sayana Press is self-administered, a viable practice given its simplified delivery system and subcutaneous administration route. Self-administration may attract new family planning users, including through the private sector, and reduce costs to serve existing DMPA users through decreased operational costs and more efficient use of resources such as providers time. Moreover, the opportunity costs for women would be reduced because they would not need to travel as often to receive a re-injection from a health care provider. DMPA clients and providers are ready to explore the potential of self-injection of Sayana Press. After administering Sayana Press during the FHI 360 acceptability studies providers spontaneously discussed the potential for self-injection of this method [1]. Additionally, almost half of Ugandan clients who received Sayana Press (45%) were moderately or very willing to self-inject the method. In Senegal, where all the clients were recruited at clinics, over a fifth (22%) said they were moderately or very willing to self-inject [2]. Previous research showed that self-injection of subcutaneous (SC) DMPA in a pre-filled glass syringe (known as Sayana, also manufactured by Pfizer, Inc. USA) was feasible and safe. In a trial conducted in New York City, women were randomized to self-administration or clinic administration of DMPA-SC. All participants but one eligible for enrollment were successful at self-administering DMPA-SC and uninterrupted continuation rates were high (47% at 12 months) compared to typical DMPA continuation rates. Continuation rates and DMPA serum levels were similar in the self-administered and clinic administered groups [5]. A study conducted in a large family planning clinic in Edinburgh, Scotland found self-administration of DMPA-SC feasible and associated with similar continuation rates and satisfaction to clinicianadministered DMPA-IM [6]. In this study, all self-injections were given within the appropriate interval. A non-comparison study conducted in Planned Parenthood clinics in Florida found continuation of selfinjected DMPA-SC high (74%) at the fourth injection [7]. Participants in this study reported the injection to be easy and convenient and were likely to recommend self-administration to other women. Given this body of data, self-injection of Sayana Press appears to be a feasible method of birth control that may be adopted by a significant number of users which in turn, may drive down the cost, a significant factor in the adoption of any contraception in low-resource settings such as Malawi. However, the feasibility of Sayana Press self-injection and the potential for this practice to increase contraceptive continuation has never been assessed in family planning programs in low-resource settings. The Malawi Ministry of Health (MOH) and the United States Agency for International Development (USAID) Malawi Mission requested the Advancing Partners and Communities (APC) project to assess self-injection of Sayana Press to inform their decision-making for procurement of Sayana Press and distribution through the health system in Malawi. This research in Malawi is timely given that injectables are the most popular method [3,8], but so is discontinuation with 33% of injectable users stopping use of the method within the first 12 months while still in need of family planning [8]. While side effects are the main reason for discontinuation (14% of all DMPA users discontinue due to side effects in Malawi), service delivery factors, especially in rural areas, impede access to DMPA re-injection 2

3 [8]. If self-injection is found feasible, the results from this research will inform self-injection training materials, messages for providers and clients, and future scale-up efforts in Malawi and elsewhere in sub-saharan Africa. Approach and Objectives FHI 360, through the Advancing Partners and Communities (APC) Project, will conduct a study in Mangochi District Malawi with the primary objective to compare continuation rates between women who self-inject Sayana Press compared to women who receive Sayana Press injections from a provider. Secondary research objectives include: 1) To compare reported side effects between the two study groups 2) To compare pregnancy rates between the two study groups 3) To describe experiences of women who self-inject Sayana Press 4) To describe experiences and recommendations of family planning providers who train women to self-inject Sayana Press Under the guidance of FHI 360, the Service Provider will implement a randomized control trial in Mangochi district of Malawi. The trial will be conducted in full compliance with Good Clinical Practice (GCP) standards. 734 eligible women attending Ministry of Health (MOH) family planning clinics or seeking family planning services from clinic family planning providers or Health Surveillance Assistants (HSAs) involved in the study will be randomized to receive either: (1) Sayana Press administered by a family planning provider, or (2) training on how to self-inject Sayana Press and the opportunity to self-inject the method at home. The eligibility criteria will be: women, aged 18-40, in general good health, able to understand and willing to sign an informed consent document, willing to provide contact information for follow-up visits and participate in up to 4 follow-up visits over the course of a year, medically eligible to receive Sayana Press according to the WHO Medical Eligibility Criteria, interested in using DMPA and willing to take Sayana Press, and willing to be randomized into one of two study arms. To enroll, new DMPA users will need to have a menstrual period that started within the past 7 days. During the enrollment visit women in the self-injection arm will be trained by family planning providers (including HSAs) to self-inject Sayana Press and will self-inject Sayana Press under supervision. Participants who successfully self-inject Sayana Press under supervision will then be given three Sayana Press units to take home. The study family planning providers will collect baseline data at the enrollment visit for all participants. In both arms, trained data collectors will collect data regarding continuation status, acceptability, adverse events, and experiences with side effects every three months for a year. These follow-up interviews will occur shortly after participants re-injection date (post 3-, 6-, and 9-months). 12-month continuation rates will be calculated using survival analysis methods. We will also track the numbers of women: invited to participate in the study, participated in the study, self-injected at the enrollment visit, and self-injected on-time during the three follow-up interviews. Approximately 12 months after the enrollment visit injection, or when participants discontinue use of Sayana Press (whichever event occurs first), data collectors will conduct a final visit to assess whether 3

4 the participants had any medical problems since their last visit and to have the participant take a pregnancy test. In addition to this quantitative data, qualitative interviews will be conducted with 30 randomly selected participants in the self-injection arm to understand participants strategies for remembering when to reinject, fidelity to Uniject activation procedures, safe injection practices, and storage and waste disposal procedures. We will also conduct interviews with 12 randomly selected family planning providers to describe their techniques and recommendations for training and supporting women to self-inject Sayana Press. Scope of Work The Service Provider will be responsible for all coordination and logistical tasks related to the planning, scheduling, and relationship-building necessary for successful completion of data collection. It is expected that the Service Provider will provide a site Principal Investigator, Study Coordinator, Field Medical Monitor (must have a current license to practice as a nurse/midwife or MD) and data collectors to complete the data collection and data transfer to FHI 360. While we require the Study Coordinator and Field Medical Monitor be physically present in the study district during the data collection period and the Study Coordinator to provide frequent updates to FHI 360, the Service Provider may suggest an alternative staffing plan with appropriate justification. The Service Provider will make arrangements for the training of all study personnel, including study providers which will be recruited from select MOH family planning clinics in the study district. The master training will be led by FHI 360, but the trainings for the study providers will be led by the Service Provider. The Service Provider will also provide logistical support to FHI 360 personnel who will make regular visits to the study clinics. Project deliverables include electronic copies of all documents and notes, all data, audio recordings, and meeting notes. Specific responsibilities and tasks include: Provide feedback on protocol, 6 Case Report Forms (CRFs), and 2 interview guides Translate 3 informed consent forms (1 ICF of 7 pages, 2 ICFs of 3 pages each), 6 CRFs (ranging from approximately 1-9 pages), and two qualitative interview guides (of approximately 2 pages each) into local language(s) as necessary Prepare and submit local IRB application and follow-up as necessary until approval is obtained. Please budget for applicable IRB fees. Facilitate appropriate insurance coverage for clinical trial participants according to national guidelines. Please budget for applicable insurance fees. Recruit and supervise study staff FHI 360 will work with the MOH to identify 6 family planning facilities to participant in the study (the District Hospital in Mangochi and 5 other MOH health facilities that provide family planning services in Mangochi). The Service Provider will be responsible for recruiting a total of 20 clinicbased family planning providers from these 6 study clinics. Ten providers should be from the District Hospital and two providers from each of the 5 other health facilities. We estimate that the District Hospital can enroll about 300 participants in 3 months and the rest of the sample could be shared amongst the 5 health facilities (average of 87 women for 3 months). Recruit 20 Health Surveillance Assistants (HSAs) who work in the communities surrounding the 6 study clinics. 4

5 Submit copies of certificates proving all study staff, including data collectors, Field Medical Monitor, Study Coordinator, site Principal Investigator and study providers (clinic-based providers and HSAs), completed and passed the tests for research ethics (RE) and ICH Good Clinical Practice (GCP). The RE and GCP curriculums have to be approved by FHI 360. Examples of acceptable curriculums include Collaborative Institutional Training Initiative (CITI) Program (available at: and online FHI 360 online research ethics training curriculum (available at: The Service Provider is expected to provide this training to any study staff who do not have current (within the last three years) certificates. Submit copies of medical credentials or certificates for all study providers, the Field Medical Monitor, and site Principal Investigator (if applicable). All study specific training will occur after RE and GCP training certificates and medical credentials are approved by FHI 360. Arrange for FHI 360-led master training of the site Principal Investigator, Study Coordinator, Field Medical Monitor, and data collectors o 2 weeks (10 consecutive business days) in length o The first 5 days will be classroom-based o Arrange for a pretest of the instrument in field sites during the last 5 days Conduct the provider trainings (we recommend this training is led by the Study Coordinator and Field Medical Monitor) on the following topics: o RE and GCP, if they don t currently have this training o Study protocol (we suggest 1.5 days) o Sayana Press self-injection (we suggest 0.5 days) o We recommend conducting this training separately for the clinic-based providers and the HSAs Introduce study to the communities by providing a study overview in the communities surrounding the 6 study clinics Enrollment interview ensuring study providers conduct enrollment/eligibility interview and self-injection training (when applicable) to enroll 734 participants. Follow-up, behavioral interviews conducted by data collectors (3 interviews for each of the 734 participants, occurs every 3 months at study clinic or at the place of the participants choosing, but should all be in Mangochi District) Final visits for each participant, with final questions asked and pregnancy test conducted at study clinic or at the place of the participants choosing Double data entry for up to 2,202 Follow-Up Interview Behavioral Forms (734 participants x 3 interviews) into EpiData data entry program. The data entry program (for the Follow-Up Interview Behavioral Form) will be developed by FHI 360 in English, but Service Provider needs to supply computers for data entry and download the EpiData program from the Internet ( prior to the master training Perform data quality checks and back-up data onto thumb drive daily Send EpiData datasets to FHI 360 on a weekly basis via Leapfile Conduct, verbatim transcribe and translate into English (if necessary) in-depth interviews with 12 study providers (one hour in length, conducted at study clinic or at the place of the participants choosing) Conduct, verbatim transcribe and translate into English (if necessary) in-depth interviews with 30 randomly selected participants from the self-injection arm (1 hour in length, conducted at study clinic or at the place of the participants choosing) 5

6 Scan and completed Case Report Forms (CRFs) to FHI 360 on a weekly basis. We anticipate having 5 CRFs for each enrolled participant that will need to be scanned and ed (Enrollment, Follow-Up Clinical Form, Final, Adverse Events, and Pregnancy). The Follow-Up Interview Behavioral Form will be entered into the EpiData program rather than scanned and ed. Collect adverse event data, at scheduled and unscheduled visits, from enrollment through until 3 months after the participant s last Sayana Press injection. Data collectors will collect AE information (except for relatedness) and the site Principal Investigator or appropriate designee evaluate all reported or observed AEs and assure that appropriate health care or referral is provided. All AEs will be assessed for seriousness and severity, relationship to study drug, and outcome to date. Report serious adverse events (SAEs) and pregnancies to FHI 360 within 24 hours of learning about the event Arrange for dissemination meeting (1 day meeting with 20 stakeholders) The Service Provider should budget for the following supplies: Six (6) Locked File Cabinets (one in each study clinic) Twenty (20) locking supply storage boxes for HSAs to store Sayana Press and study documents Cost for printing of the following IDI guides and ICFs: o IDI guide 1: 12 x 2 pages = 24 pages o IDI guide 2: 30 x 2 pages = 60 pages o Main study ICF: 807 x 7 pages = 5,395 pages o IDI 1 ICF: 15 x 3 pages = 45 pages o IDI 2 ICF: 39 x 3 pages = 117 pages o Total = approximately 5,644 pages Printing costs for all training materials Small cardboard sharps disposal boxes for study participants enrolled in the self-injection arm Pregnancy tests for use at final visit and where appropriate throughout the study for cases where participants return to the clinic with a suspected pregnancy Study participant compensation 734 participants x 5 interviews x $3 = $11,010 In-depth interview compensation 12 study providers x $6 =$72 In-depth interview compensation 30 self-injector participants x $6 = $180 Provider Incentives for recruitment - $10/month for 3 months x 40 study providers = $1,200 Responsibilities of FHI 360: 1. Creation and provision of electronic version of protocol, study manual, all CRFs, interview guides and consent forms, in English 2. Selection of 6 study clinics 3. Provision of EpiData data entry program (for the Follow-Up Interview Behavioral Form) 4. Provision of randomization envelopes 5. Provision of printed Case Report Forms (CRFs) in English 6. Trainers for master training of the site Principal Investigator, Study Coordinator, Field Medical Monitor, and data collectors 7. Provision of electronic training materials for use during the study provider trainings (to be conducted by Service Provider) 6

7 8. Provision of electronic version of Sayana Press self-injection training materials (Service Provider needs to make copies) 9. Provision of study product (Sayana Press units) Additional duties and responsibilities In conducting the field implementation, the Service Provider will: abide by any required guidelines for human subjects research as determined by either FHI 360 or local, provincial or national governmental bodies; and ensure professional and friendly behavior during interactions with study participants. FHI 360 reserves the right to modify the assessment strategy (and this SOW) at any time, based on results and experience. Expected Timeline Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Review protocol/instruments Obtain IRB approval Obtain RE, GCP and medical certificates for study staff Conduct study staff trainings Recruit and Conduct Enrollment interviews Conduct Follow-up interviews (3 visits per participant) Conduct Final Visits Scan and CRFs weekly Enter data into EpiData and 7

8 weekly Conduct interviews with providers Conduct interviews with self-injectors Transcribe, translate and transmit indepth interview data Review study findings Disseminate findings in Malawi Deliverable Schedule Deliverable Estimated Completion Date: Provide feedback on protocol, informed consent Oct 2014 forms, CRFs, and interview guides Translate study documents (informed consent, CRFs, Oct 2014 interview guides) Obtain IRB approval Nov 2014 Obtain insurance coverage for clinical trial Dec 2014 participants Recruit 20 clinic-based family planning providers Dec 2014 (nurses/midwives) from 6 identified MOH clinics and 20 HSAs working in the communities surrounding the study clinics all experienced DMPA IM providers Ethics and GCP training certificates submitted for all Dec 2014 study staff and medical credentials/certificates for study providers and relevant study staff Arrange for FHI 360-led master training and pretesting Jan 2015 Service Provider-led study provider trainings Jan 2015 conducted Introduce study in communities Jan 2015 Eligibility/ Enrollment visits conducted by study April 2015 providers for all 734 participants and CRFs completed Follow-up interviews (post 3-, 6-, and 9-month Feb

9 injections) conducted by data collectors and CRFs completed Final visits conducted by data collectors and CRFs completed Scanned CRFs sent weekly through secure transmission Double data entry of Follow-Up Interview Behavioral Forms into EpiData EpiData datasets sent to FHI 360 through secure June 2016 Jan 2015 June 2016 April 2015 Feb 2016 April 2015 Feb 2016 transmission IDIs conducted with 12 study providers May 2015 Provider IDIs transcribed and translated May 2015 IDIs conducted with 30 self-injecting participants June 2016 Participant IDIs transcribed and translated July 2016 All IDI transcript sent to FHI 360 through secure July 2016 transmission Hold 1-day dissemination meeting November 2016 Review presentations and reports of study findings November 2016 prepared by FHI 360 Final Report on data collection experience submitted November 2016 Duration and Location The work is expected to span 26 months, beginning in the fall of The anticipated study duration is 18 months. The training and study will be conducted in Mangochi, Malawi. Qualifications and Experience The Study Coordinator must have the following qualifications and experience: Speak and write fluent English 10+ years of experience coordinating large-scale research projects for international clients Demonstrated experience following specific research protocols Post-graduate education Available to work on the study full-time for the entire duration The Field Medical Monitor must have the following qualifications and experience: Speak English and a local language if necessary in the study district A current license to practice medicine as a nurse/midwife or MD in the study district Must be physically present in study district to be able to respond to SAEs Experience in providing family planning, including DMPA to clients Experience teaching other providers about family planning methods Have demonstrated experience following specific research protocols The Data Collectors must have the following qualifications and experience: 9

10 Speak English and a local language if necessary in the study district Have experience collecting quantitative survey data and conducting qualitative in-depth interviews (Service Provider may propose separate individuals for the quantitative and qualitative data collection activities) Have demonstrated experience following specific research protocols University-level education SUBMISSION REQUIREMENTS To be considered, bidders must provide the following: 1. Description of methodology and proposed approach for the research as described in the Scope of Work section above (max 3 pages). Agencies should demonstrate: a. solid experience in conducting public health studies, including GCP randomized clinical trials. b. the ability to submit and obtain ethics approval for similar research. c. the ability to reach and connect with ethics committees, regulatory agencies, and government officials (to obtain necessary authorizations for data collection). Agencies must also provide a description of location(s) of presence relevant to this RFP. Agencies with research experience in identified regions are preferred. 2. Company profile with solid background/knowledge in public health, particularly family planning in Malawi (and/or other neighboring countries). 3. CV or resumes for key personnel 4. Budget, including proposed labor costs, expenses, and other direct costs. All quotes should be in local currency with the appropriate conversion to USD outlined. To the extent that indirect costs are applicable, they are subject to the following limits: 0% for government agencies, other private foundations and for-profit organizations up to 10% for U.S. universities and other academic institutions Up to 15% for all other non-u.s. academic institutions and all private voluntary and nongovernment organizations, regardless of location. Indirect cost rates (and the limitations) apply both to the primary applicant organization and any sub-grantees and/or sub-contractors that are part of the proposal. 5. Three references, including contact information for each. The references should be for past customers for whom similar work was done. 6. An address where we may send a confirmation of receipt of your submission. 7. If available, include a financial statement audit of the organization s most recent fiscal year, conducted by a third-party accounting firm. CRITERIA FOR EVALUATION 10

11 Bids will be evaluated and ranked by a committee on a best-value basis according to the criteria below. Only offers able to provide all of requirements listed above will be considered. Selection shall be based on the following weighted categories: 1. Methodology and Proposed Approach for the Research: 30% 2. Capacity and Experience: 20% 3. Completeness and Appropriateness of the Budget: 30% 4. References: 20% NOTE: FHI 360 will not compensate the company for its preparation of response to this RFP nor is the issuing of this RFP a guarantee that FHI 360 will award a contract. Instructions and Deadline Responses to this RFP should be submitted by to Dr. Holly Burke (hburke@fhi360.org) and Ms. Jennifer Headley (jheadley@fhi360.org) no later than September 25th. Please follow the instructions carefully. Proposals which do not follow these instructions will not be reviewed. Offers received after this date and time will not be accepted for consideration. FHI 360 will acknowledge receipt of your proposal by . Proposals must be submitted in electronic format using Microsoft Office compatible software. FHI 360 will accept questions from interested parties through the date specified on page 1 via at hburke@fhi360.org and jheadley@fhi360.org. Withdrawal of Proposals Proposals may be withdrawn by written notice or received at any time before award. False Statements in Offer Offers must provide full, accurate and complete information as required by this solicitation and its attachments. Proposals become property of FHI 360. DISCLAIMERS AND FHI 360 PROTECTION CLAUSES FHI 360 may cancel the solicitation and not make an award FHI 360 may reject any or all responses received Issuance of a solicitation does not constitute an award commitment by FHI Solutions FHI 360 reserves the right to disqualify any offer based on offer or failure to follow solicitation instructions FHI 360 will not compensate offers for response to solicitation 11

12 FHI 360 reserves the right to issue an award based on initial evaluation of offers without further discussion FHI 360 may choose to award only part of the activities in the solicitation, or issue multiple awards based on the solicitation activities FHI 360 may request from short-listed offerors a second or third round of either oral presentation or written response to a more specific and detailed scope of work that is based on a general scope of work in the original RFP. FHI 360 has the right to rescind an RFP, or rescind an award prior to the signing of a subcontract due to any unforeseen changes in the direction of FHI 360 s client, be it funding or programmatic. FHI 360 reserves the right to waive minor proposal deficiencies that can be corrected prior to award determination to promote competition FHI 360 will be contacting offerors to confirm contact person, address and that bid was submitted for this solicitation. REFERENCES 1. Burke HM, Mueller MP, Packer C, Perry B, Bufumbo L, et al. (2014) Provider acceptability of Sayana(R) Press: results from community health workers and clinic-based providers in Uganda and Senegal. Contraception 89: Burke HM, Mueller MP, Perry B, Packer C, Bufumbo L, et al. (2014) Observational study of the acceptability of Sayana(R) Press among intramuscular DMPA users in Uganda and Senegal. Contraception 89: National Statistical Office, (NSO), and ICF Macro (2011) Malawi Demographic and Health Survey Zomba, Malawi, and Calverton, Maryland, USA: NSO and ICF Macro. 4. National Statistical Office, (NSO), and ICF Macro (1994) Malawi Demographic and Health Survey Zomba, Malawi, and Calverton, Maryland, USA: NSO and ICF Macro. 5. Beasley A, White KO, Cremers S, Westhoff C (2014) Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception 89: Cameron ST, Glasier A, Johnstone A (2012) Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 85: Prabhakaran S, Sweet A (2012) Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception 85: National Statistical Office, (NSO), and ICF Macro (2005) Malawi Demographic and Health Survey Zomba, Malawi, and Calverton, Maryland, USA: NSO and ICF Macro. 12